Treatment effects of monthly intravenous immunoglobulin on patients with relapsing - remitting Multiple Sclerosis: Further analyses of the Austrian immunoglobulin in MS Study

Abstract

Recently, the Austrian Immunoglobulin in Multiple Sclerosis (AIMS) study showed patients with relapsing - remitting multiple sclerosis to benefit from repeated administration of intravenous immunoglobulin (IVIg). To provide a more detailed understanding of IV/g's action we performed further analyses on the time course of treatment effects and in regard to the impact of clinical disability at study entry on patients' response to medication. The AIMS trial was a randomized, placebo-controlled, double blind, multicenter trial. It included 148 patients (IVIg : 75; placebo 73) who suffered from relapsing-remitting MS, were 15-65 years old and scored from I -6 on the Expanded Disability Status Score (EDSS). IVIg was given over 2 years in a monthly dosage of 0.15 - 0.2 g/kg body weight. Within the first 6 months of the trial clinical disability of IVIg treated patients improved significantly from a baseline EDSS of 3.33 ± 1.38 to a score of 3.05 ± 1.73 (P=0.002). This improvement was retained over the subsequent 18 months of the trial (final EDSS: 3.09 ± 1.62). In contrast, placebo-treated patients showed a slight trend for deterioration over the study period (baseline EDSS: 3.37± 1.67; final EDSS: 3.49± 1.83). IVIg treatment was associated with a significant reduction of relapses throughout the study which was independent of the patients' disability at baseline. The observation of clinical improvement in the early phase of IVIg medication may suggest the activation of repair mechanisms such as the promotion of remyelination while immunoregulatory effects would be expected as the cause of fewer exacerbations throughout the AIMS study. These hypotheses need to be tested in future trials.

Keywords

baseline disability intravenous immunoglobulin relapsing-remitting MS remyelination time course of treatment effects

Get full access to this article

View all access options for this article.

References

Hafler DA , Weiner HL MS. a CNS and systemic autoimmune disease . Immunol Today 1989; 10: 104-107.

Martin R. , McFarland HF Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis . Crit Rev Clin Lab Sci 1995; 32: 121-182.

Giovannoni G. , Hartung H-P. The immunopathogenesis of multiple sclerosis and Guillain-Barré syndrome . Curr Opin Neurol 1996; 9: 165 -177.

Van Der Meché Fga , Schmitz Pim , and the Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome . N Engl J Med 1992; 326: 1123-1129.

Vermeulen M. et al. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study . J Neurol Neurosurg Psychiatry 1993; 56: 36-39.

Dalakas MC et al. A controlled trial of high dose intravenous immune globulin infusions as treatment for dermatomyositis . N Engl J Med 1993; 329: 1993- 2000.

Rothfelder U. , Neu I. , Pelka R. Therapy of multiple sclerosis with immunoglobulin G . MMW Munch Med Wochenschr 1982; 124: 74 - 78.

Schuller E. , Govaerts A. First results of immunotherapy with immunoglobulin G in multiple sclerosis patients . Eur Neurol 1983; 22: 205 - 212.

Soukop W. , Tschabitscher H. Gamma globulin therapy in multiple sclerosis. Theoretical considerations and initial clinical experiences with 7S immunoglobulins in MS therapy . Wien Med Wochenschr 1986; 136: 477-480.

10.

Achiron A. et al. Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis . Arch Neurol 1992; 49: 1233-1236.

11.

Achiron A. et al. Intravenous gammaglobulin treatment in multiple sclerosis and experimental autoimmune encephalomyelitis : delineation of usage and mode of action . J Neurol Neurosurg Psychiatry 1994 ; 57: S57-61.

12.

Fazekas F. et al. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis . Lancet 1997; 349: 589-593.

13.

Poser CM et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols . Ann Neurol 1983; 13: 227-231.

14.

Hauser SL Multiple sclerosis and other demyelinating diseases. In: Isselbacker KJ et al. (eds.). Harrison's Principles of Internal Medicine, vol 2. McGraw-Hill: New York 1994; pp 2287-2295.

15.

Kurtzke JF Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) . Neurology 1983; 33: 1444-1452.

16.

Bornstein MB et al. A pilot trial of COP 1 in exacerbating-remitting multiple sclerosis . N Engl J Med 1987; 317: 408-414.

17.

Rodriguez M. , Miller DJ , Lennon VA Immunoglobulins reactive with myelin basic protein promote CNS remyelination . Neurology 1996; 46: 538-545.

18.

van Engelen Bgm et al. Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis . Ann Neurol 1992; 32: 835-836.

19.

Tenser RB , Hay KA , Aberg JA Immunoglobulin G immunosuppression of multiple sclerosis. Suppression of all three major lymphocyte subsets . Arch Neurol 1993; 50: 417-420.

20.

Jungi TW et al. Effect of IgG for intravenous use on Fc receptor mediated phagocytosis by human monocytes . Clin Exp Immunol 1990 ; 82: 163-169.

21.

Frank MM , Basta M. , Fries LF The effect of intravenous immune globulin on complement-dependent immune damage of cells and tissues . Clin Immunol Immunpathol 1992; 62: S82 - 86.

22.

Anderson UG , Bjork L. , Skansen-Saphir U. , Anderson JP Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG . Immunol 1993; 79: 211- 216.

23.

The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS / MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial . Neurology 1995; 45: 1277-1285.

24.

Johnson KP et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial . Neurology 1995; 45: 1268-1276.

25.

Noseworthy JH , O'Brien PC , van Engelen Bgm , Rodriguez M. Intravenous immunoglobulin therapy in multiple sclerosis: progress from remyelination in the Theiler's virus model to a randomised, double-blind, placebo-controlled clinical trial . J Neurol Neurosurg Psychiatry 1994; 57: S11 - 14.

26.

Soelberg Sörensen P. et al. A double-blind cross-over trial of intravenous immunoglobulin in multiple sclerosis: preliminary results . Europ J Neurol 1996; 3: S34 - 35 (abstract).